• BensBlog.LIVE

Innovation Pharmaceuticals Poised to Reuse Agent for COVID-19 Vaccine

Innovation Pharmaceuticals is investigating an FDA approved agent as a COVID-19 Vaccine.

The vaccine candidate, Brilacidin, is a potential novel coronavirus (COVID-19) treatment, one of the few promising drugs targeting COVID-19 that has been tested in FDA clinical trials for other indications, potentially enabling its expedited use against COVID-19.

Brilacidin is an immunomodulatory agent with anti-inflammatory/antibiotic properties. It is Innovation's lead drug candidate in its defensin-mimetic franchise.

The Company also has successfully completed a Phase 2 trial of Brilacidin in Oral Mucositis, aligning with the FDA on a planned Phase 3 program.

According to CNN,

On the virus treatment front, doctors are agonizing over the possibility they may have to ration the use of remdesivir, that experimental drug that could be used to treat Covid-19 patients. Meanwhile, another study has found hydroxychloroquine, the drug touted by some politicians as a potential treatment, is not effective against the disease.

49 views0 comments

(731) DAM-ESEQue

©2019 by Meye Feye LLC. Powered by 276Productions.Top

This site was designed with the
website builder. Create your website today.
Start Now